Revvity Inc. Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/3/2026)
| Balance Sheet | Total Assets | 12,168,400,000.00 | ROE | 59.58 % |
| Balance Sheet | Total Equity | 7,250,360,000.00 | ROA | 1.99 % |
| Cashflow | Capital Expenditures | -73,522,000.00 | P/FCF | 33.88 |
| Cashflow | Free Cash Flow | 508,255,008.00 | – | – |
| Cashflow | Operating Cash Flow | 581,777,000.00 | P/CF | 29.60 |
| Income | Earnings per Share (diluted) | 2.13 | Div. Yield | 0.18 % |
| Income | Net Income | 241,675,000.00 | P/E | 71.42 |
| Income | Shares Outstanding | 113,214,000.00 | P/B | 2.38 |
| Income | Total Revenue | 2,856,050,000.00 | P/S | 6.03 |
Ratios calculated on: 10/14/2026
Company Description
PerkinElmer, Inc. is a provider of technology, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. Through the Company's advanced technologies, solutions, and services, it addresses issues related to health and safety of people and their environment. It operates in two segments: Human Health and Environmental Health. In February 2011, it acquired chemagen Biopolymer-Technologie AG (chemagen). In March 2011, it acquired ArtusLabs, Inc. (ArtusLabs). In March 2011, it acquired specified assets and assumed specified liabilities of ID Biological Systems, Inc. (IDB). In April 2011, it acquired CambridgeSoft Corporation (CambridgeSoft). In May 2011, it acquired Geospiza, Inc. (Geospiza). In May 2011, it acquired Labtronics, Inc. (Labtronics). In June 2011, it acquired Dexela Limited (Dexela). In November 2011, it acquired Caliper Life Sciences, Inc. (Caliper).
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.perkinelmer.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more